Literature DB >> 25894596

Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.

Matthieu Peyre1, Marc Zanello, Karima Mokhtari, Anne-Laure Boch, Laurent Capelle, Alexandre Carpentier, Stephane Clemenceau, Carine Karachi, Soledad Navarro, Aurelien Nouet, Vincent Reina, Charles-Ambroise Valery, Marc Sanson, Philippe Cornu, Michel Kalamarides.   

Abstract

Patients with surgery- and radiation-refractory meningiomas have a poor outcome. Due to our lack of knowledge concerning multi-recurrent meningioma natural history, their clinical course is poorly defined. This retrospective study aims at defining patterns of relapse in order to help in the definition of response criteria in future clinical trials. We performed a retrospective review of surgery- and radiotherapy-refractory meningioma cases with interpretable radiological follow-up treated in our department. Tumor volumes were measured on 3D T1 Gadolinium volumetric sequences using a semi-automated algorithm for tumor segmentation. Twenty nine patients with multi-treated meningioma (11 WHO Grade II, 5 de novo WHO Grade III and 13 transformed WHO Grade III), were evaluated. Median PFS was 16 months for patients with Grade II meningiomas. In patients with Grade III meningiomas, the de novo subgroup had a median PFS of 4 months compared with 7 months in patients with malignant transformation. Volumetric analysis of tumor growth concerned 95 tumor nodules in 50 relapses. The mean growth rate of tumor nodules was 10.4 cm(3)/year (95% CI 7.3-14.8 cm(3)/year). Three patterns of tumor growth were described: "classical" for 9 (31%) patients, "local multi-nodular" for 6 (21%) patients and "multi-nodular metastatic" for the last 14 (48%) patients. Considering all tumor nodules, median time to tumor progression (TTP) was 3.7 months. Progressing tumors represent the most frequent histological subgroup of surgery and radiation-refractory meningiomas while tumors with multi-nodular metastatic dissemination are the prominent radiological pattern of progression.

Entities:  

Mesh:

Year:  2015        PMID: 25894596     DOI: 10.1007/s11060-015-1778-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 2.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

3.  Semiautomatic segmentation and follow-up of multicomponent low-grade tumors in longitudinal brain MRI studies.

Authors:  Lior Weizman; Liat Ben Sira; Leo Joskowicz; Daniel L Rubin; Kristen W Yeom; Shlomi Constantini; Ben Shofty; Dafna Ben Bashat
Journal:  Med Phys       Date:  2014-05       Impact factor: 4.071

4.  Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.

Authors:  Michael E Sughrue; Nader Sanai; Gopal Shangari; Andrew T Parsa; Mitchel S Berger; Michael W McDermott
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

Review 5.  The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.

Authors:  Marc C Chamberlain
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

6.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

7.  Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.

Authors:  Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

Review 8.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

9.  A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.

Authors:  Susan L McGovern; Kenneth D Aldape; Mark F Munsell; Anita Mahajan; Franco DeMonte; Shiao Y Woo
Journal:  J Neurosurg       Date:  2010-05       Impact factor: 5.115

10.  Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

Authors:  Wenli Cai; Ara Kassarjian; Miriam A Bredella; Gordon J Harris; Hiroyuki Yoshida; Victor F Mautner; Ralph Wenzel; Scott R Plotkin
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

View more
  3 in total

1.  Evaluation of Magnetic Resonance Imaging for Microsurgical Efficacy and Relapse of Rolandic Meningioma.

Authors:  Peng Cao; Nianhua Wang
Journal:  Comput Intell Neurosci       Date:  2022-06-06

2.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.

Authors:  Thomas Graillon; Loic Ferrer; Jason Siffre; Marc Sanson; Matthieu Peyre; Hadrien Peyrière; Grégory Mougel; Didier Autran; Emeline Tabouret; Dominique Figarella-Branger; Anne Barlier; Michel Kalamarides; Henry Dufour; Thierry Colin; Olivier Chinot
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.